Journal of Critical Care
Volume 25, Issue 1 , Pages 69-77 , March 2010

Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia

  • Anthony M. Nicasio, PharmD

      Affiliations

    • Center for Antiinfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    • ,
  • Kathryn J. Eagye, MPH

      Affiliations

    • Center for Antiinfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    • ,
  • David P. Nicolau, PharmD, FCCP, FIDSA

      Affiliations

    • Center for Antiinfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    • Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA
    • ,
  • Eric Shore, MD

      Affiliations

    • Division of Pulmonary/Critical Care, Hartford Hospital, Hartford, CT, USA
    • University of Connecticut, School of Medicine, Farmington, CT 06030, USA
    • ,
  • Marc Palter, MD

      Affiliations

    • Division of Neurosurgery/Critical Care, Hartford Hospital, Hartford, CT, USA
    • ,
  • Judith Pepe, MD

      Affiliations

    • Division of Surgery/Critical Care, Hartford Hospital, Hartford, CT, USA
    • University of Connecticut, School of Medicine, Farmington, CT 06030, USA
    • ,
  • Joseph L. Kuti, PharmD

      Affiliations

    • Center for Antiinfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 860 545 3612; fax: +1 860 545 3992.

References 

  1. Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33:2184–2193
  2. American Thoracic Society and the Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416
  3. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262–268
  4. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006;27:158–164
  5. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infections: a meta-analysis. J Crit Care. 2008;23:91–100
  6. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531–539
  7. Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiological data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006;130:787–793
  8. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29:1109–1115
  9. Soo Hoo GW, Wen YE, Nguyen TV, et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest. 2005;128:2778–2787
  10. Gillespie EL, Kuti JL, Nicolau DP. When “S” doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections. Conn Med. 2005;69:203–210
  11. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36:S42–S50
  12. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–629
  13. Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40:219–223
  14. Lodise TP, Lomaestro BM, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–363
  15. Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther. 2007;29:2433–2439
  16. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089–1096
  17. Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007;27:333–342
  18. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–655
  19. Lancaster JW, Lawrence KR, Fong JJ, et al. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. Pharmacotherapy. 2008;28:852–862
  20. Kuti JL, Moss KM, Nicolau DP, et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. 2004;24:1641–1645
  21. Kuti JL, Dandekar PK, Nightingale CH, et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharm. 2003;43:1116–1123
  22. Tam VH, Louie A, Lomaestro BM, et al. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiological surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003;23:291–295
  23. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004;48:125–130
  24. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888–1895
  25. Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy. Curr Med Chem. 2008;15:517–522

☆ This study was partially funded by AstraZeneca Pharmaceuticals LP, Wilmington, Del. E-test strips were graciously donated by AB Biodisk, Solna, Sweden. Drs Nicolau and Kuti are members of the speakers bureau, hired as consultants, and received research funding from AstraZeneca LP. All other authors have nothing to disclose.

PII: S0883-9441(09)00072-0

doi: 10.1016/j.jcrc.2009.02.014

Journal of Critical Care
Volume 25, Issue 1 , Pages 69-77 , March 2010

Article Tools